Title
Gene Therapy for Providers 301
Release Date
July 01, 2022
Expiration Date
The estimated time to complete this activity is 60 minutes.
Purpose Statement
The purpose of this activity is to enable HTC multidisciplinary staff and hospital staff to support patients and their families as they consider hemophilia gene therapy, including education of patients and families on basic concepts in hemophilia gene therapy; administrative preparedness for providers; and short- and long-term care demands.
Activity Description
This learning activity is a process-oriented intermediate course that will guide HTC staff through the steps an institution must take to prepare to administer hemophilia gene therapy upon commercial availability of these products.
Target Audience
This enduring material is intended for physicians, physician assistants, nurses, nurse practitioners, physical therapists, social workers, pharmacists, and infusion room staff.
Educational Objectives
At the conclusion of this enduring material, the participants should be better able to:
- Discuss introductory concepts in hemophilia gene therapy
- Outline the process of preparing patients, hemophilia treatment centers, and hospital systems for the administration of gene therapy
- Explain the steps necessary for multidisciplinary team members to engage in shared patient-centered and population focused problem solving when procuring a hemophilia gene therapy product, preparing the product, and infusing the patient safely
- Discuss short term monitoring, specifically immediately after infusion and during the first three months of follow up
- Discuss long term monitoring, specifically from 3 to 24 months post infusion and > 24 months post infusion
Faculty
- Doris V. Quon, MD
- Lindsey A. George, MD
Contact Information
System Requirements
- 2 gigabytes of RAM
- High-speed internet connection
- Internet browser (current version) Firefox, Safari, Chrome, or Explorer
- Cookies and JavaScript must be enabled in the browser
